Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.

M, Heisen; MJ, Treur; HE, Heemstra; EBW, Giesen; MJ, Postma

doi:10.1080/13696998.2017.1331912

Public

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.

Published in Journal of medical economics • Jun 25, 2017

Authors:

Heisen M

Treur MJ

Heemstra HE

Abstract

<h4>Background</h4>Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting...

View

Open Access

Subject

Pulmonary embolism

Netherlands

Venous Thromboembolism

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!